InvestorsHub Logo
Followers 170
Posts 17660
Boards Moderated 0
Alias Born 03/02/2012

Re: buythebuy post# 42183

Wednesday, 07/17/2019 9:31:00 AM

Wednesday, July 17, 2019 9:31:00 AM

Post# of 112397
Agree! Won't sell until FDA approves Hulogix flagship product...

Seriously, IGEX could go to dollar-land if this drug gets approved!

BOOM! Email From DR. JAMES HUGHES...

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149534956

Chris:

Thank you for your interest. I think it's only appropriate to share my CV and I am very excited to talk about epigenetic medicine. If you are not familiar with epigenetics, it is the area of molecular and cellular biology that regulates the expression of genes. Very little of what we are is under the direct control of our genes, but rather, how and when and to what degree our genes are expressed. In fact, of the more than 7000 human diseases that are linked to our genome, only 6 diseases are due to specific DNA mutations in the structural component of the operon (the part of the gene that produces the altered protein that causes the disease). "Lifestyle risk diseases" as defined by the CDC, like obesity, Diabetes II; asthma, addiction, ocular disease, etc are the result of environmentally directed changes to other areas of the operon, particularly promoter sequences upstream from the structural gene that regulate expression of the gene. The mechanism of change is an alteration in the tertiary structure of the promoter sequence, and not an actual alteration in the DNA sequence. Thus epigenetic mechanisms help an organism with a static DNA complement (genome) to adapt to changes in their environment. To get back to disease mechanisms, the problem is that our genome is not compatible with the environment that we have created. Hulogix has dedicated itself to correcting aberrant genomic expression predisposing individuals to disease by identifying and correcting key epigenetic elements.

Our flagship product has completed safety and efficacy trials, an NADA has been submitted and Phase II clinical trials are underway. We have two products that have had provisional patents and one additional product for which a non-provisional patent is pending. That is as much as I feel comfortable sharing at this time. I will forward your request to our board, and provide more information, including my personal CV upon their discretion.


HuLogix Logomini

"We have created an environment in which we are no longer able to thrive"

J. Ulrick Hughes, DVM, MS

Hulogix, Inc

www.hulogix.com